Next-generation ctDNA-driven clinical trials in precision immuno-oncology

被引:1
作者
Aggarwal, Charu [1 ]
Leighl, Natasha B. [2 ]
机构
[1] Univ Penn, Dept Med, Div Hematol Oncol, Philadelphia, PA 19104 USA
[2] Princess Margaret Hosp Div, Toronto, ON, Canada
关键词
biomarkers; tumor;
D O I
10.1136/jitc-2022-006397
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
引用
收藏
页数:3
相关论文
共 5 条
  • [1] Dynamics of Tumor and Immune Responses during Immune Checkpoint Blockade in Non-Small Cell Lung Cancer
    Anagnostou, Valsamo
    Forde, Patrick M.
    White, James R.
    Niknafs, Noushin
    Hruban, Carolyn
    Naidoo, Jarushka
    Marrone, Kristen
    Sivakumar, I. K. Ashok
    Bruhm, Daniel C.
    Rosner, Samuel
    Phallen, Jillian
    Leal, Alessandro
    Adleff, Vilmos
    Smith, Kellie N.
    Cottrell, Tricia R.
    Rhymee, Lamia
    Palsgrove, Doreen N.
    Hann, Christine L.
    Levy, Benjamin
    Feliciano, Josephine
    Georgiades, Christos
    Verde, Franco
    Illei, Peter
    Li, Qing Kay
    Gabrielson, Edward
    Brock, Malcolm V.
    Isbell, James M.
    Sauter, Jennifer L.
    Taube, Janis
    Scharpf, Robert B.
    Karchin, Rachel
    Pardoll, Drew M.
    Chaft, Jamie E.
    Hellmann, Matthew D.
    Brahmer, Julie R.
    Velculescu, Victor E.
    [J]. CANCER RESEARCH, 2019, 79 (06) : 1214 - 1225
  • [2] Sivapalan L., 2022, J IMMUNOTHER CANCER
  • [3] Serial Monitoring of Circulating Tumor DNA by Next-Generation Gene Sequencing as a Biomarker of Response and Survival in Patients With Advanced NSCLC Receiving Pembrolizumab-Based Therapy
    Thompson, Jeffrey C.
    Carpenter, Erica L.
    Silva, Benjamin A.
    Rosenstein, Jamie
    Chien, Austin L.
    Quinn, Katie
    Espenschied, Carin R.
    Mak, Allysia
    Kiedrowski, Lesli A.
    Lefterova, Martina
    Nagy, Rebecca J.
    Katz, Sharyn, I
    Yee, Stephanie S.
    Black, Taylor A.
    Singh, Aditi P.
    Ciunci, Christine A.
    Bauml, Joshua M.
    Cohen, Roger B.
    Langer, Corey J.
    Aggarwal, Charu
    [J]. JCO PRECISION ONCOLOGY, 2021, 5 : 510 - 524
  • [4] Changes in Circulating Tumor DNA Reflect Clinical Benefit Across Multiple Studies of Patients With Non-Small-Cell Lung Cancer Treated With Immune Checkpoint Inhibitors
    Vega, Diana Merino
    Nishimura, Katherine K.
    Zariffa, Nevine
    Thompson, Jeffrey C.
    Hoering, Antje
    Cilento, Vanessa
    Rosenthal, Adam
    Anagnostou, Valsamo
    Baden, Jonathan
    Beaver, Julia A.
    Phd, Aadel A. Chaudhuri Md
    Chudova, Darya
    Fine, Alexander D.
    Fiore, Joseph
    Hodge, Rachel
    Hodgson, Darren
    Hunkapiller, Nathan
    Klass, Daniel M.
    Kobie, Julie
    Pena, Carol
    Pennello, Gene
    Peterman, Neil
    Philip, Reena
    Quinn, Katie J.
    Raben, David
    Rosner, Gary L.
    Sausen, Mark
    Tezcan, Ayse
    Xia, Qi
    Yi, Jing
    Young, Amanda G.
    Stewart, Mark D.
    Carpenter, Erica L.
    Aggarwal, Charu
    Allen, Jeff
    [J]. JCO PRECISION ONCOLOGY, 2022, 6
  • [5] IMpower010: Biomarkers of disease-free survival (DFS) in a phase III study of atezolizumab (atezo) vs best supportive care (BSC) after adjuvant chemotherapy in stage IB-IIIA NSCLC
    Zhou, C.
    Das Thakur, M.
    Srivastava, M. K.
    Zou, W.
    Xu, H.
    Ballinger, M.
    Felip, E.
    Wakelee, H.
    Altorki, N. K.
    Reck, M.
    Liersch, R.
    Kryzhanivska, A.
    Harada, M.
    Tanaka, H.
    Hamm, J.
    McCune, S.
    McNally, V.
    Bennett, E.
    Gitlitz, B.
    Novello, S.
    [J]. ANNALS OF ONCOLOGY, 2021, 32 : S1374 - S1374